Company Overview and News
Shocking video shows a young girl being thrown out of her father's car on a highway in eastern China last week.
The Company seeks to provide investors with a high level of dividends as well as capital appreciation over the long term, from a diversified portfolio of investments traded on the Pacific, Australasian, Japanese and Indian stock markets ('Asia Pacific region').
Toll roads are among the oldest businesses in the world. The idea of collecting a fee for the right of passage is several thousand years old. Nearly three thousand years ago, travelers had to pay a toll for using the Susa–Babylon highway under the regime of Ashurbanipal, who reigned in the seventh century BC. The business of toll collection has survived through the ages.
The board of the Irish Stock Exchange approves the admission of the undermentioned securities to listing on the Official List and trading on the Main Securities Market of the ISE.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
EMCOR Group Inc. (EME - Analyst Report) continued with its choppy earnings history with its bottom line missing estimates in first-quarter 2016. The company reported adjusted earnings from continuing operations of 57 cents per share, which lagged the Zacks Consensus Estimate of 58 cents by 1.7%. However, the figure fared better year over year, surpassing the year-ago tally of 52 cents by 9.6%.
Chicago Bridge & Iron Company N.V. (CBI - Analyst Report) reported first-quarter 2016 adjusted earnings of $1.01 per share, which significantly lagged the Zacks Consensus Estimate of $1.14. However, the bottom line compared favorably with the year-ago figure of 96 cents per share (excluding the effect of divested operations).
The Company does not have a formal benchmark. It uses the FTSE All-World Asia Pacific ex Japan Index (sterling adjusted) for reference purposes only.
Shares of MasTec, Inc. (MTZ - Analyst Report) scaled a new 52-week high of $21.53 on Apr 13, eventually closing the day’s trading at $21.50. The stock price appreciation came on the back of benefits expected from strategic acquisitions and a strong backlog. Increased mobile data traffic will also drive demand. This provider of construction services has a market cap of $1.7 billion. Meanwhile, average volume of shares traded over the last three months is approximately 1009K.
On Apr 11, we issued an updated research report on MasTec, Inc, (MTZ - Analyst Report), a leading infrastructure construction company operating in the U.S. The company is engaged in building, installation, maintenance and upgrade of energy, communication and utility infrastructure. We remind investors that MasTec performed poorly in fourth-quarter 2015 with adjusted earnings (excluding one-time items barring non-cash stock compensation expense) plunging 50% to 18 cents per share from 36 cents per share earned in the prior-year quarter.
Primoris Services Corporation (PRIM - Snapshot Report) declared a new five-year Master Service Agreement (“MSA”) worth $500 million from a California utility customer. The contract was secured jointly by the Underground and Industrial divisions of ARB, Inc., part of the West Construction Services segment of Primoris. The engineering, procurement, and construction (“EPC”) agreement involves all lines of the utility’s business, including both gas and electric transmission and distribution.
James Construction Group, a unit of the East Construction Services segment of Primoris Services Corporation (PRIM - Snapshot Report), has secured three new heavy civil contracts worth $18 million. The projects were awarded by the Texas Department of Transportation. Under the first contract, Primoris will build northbound auxiliary lanes on SH 71 in Colorado County, TX. Scope of the project also includes earthwork, treated subgrade, base and approximately 65,000 tons of asphalt paving.
Shares of Primoris Services Corporation (PRIM - Snapshot Report) scaled a new 52-week high of $25.25 on Mar 18, eventually closing lower at $25.13. The new high came on the back of benefits expected from project execution and backlog growth. Primoris has a market cap of $1.3 billion. Average volume of shares traded over the last three months is around 228K. The company’s stock flaunts a one-year return of about 43% and a year-to-date return of around 14%.
Profits seen as being less sensitive to economic slowdown
Exhibit-99.CERT CERTIFICATION I, Shaun P. Mathews, certify that: 1. I have reviewed this report on Form N-Q of Voya International High Dividend Equity Income Fund; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...